An open-label, efficacy and safety study of i.v. evinacumab in patients aged ≥12 years who completed a parent study, with follow up to 192 weeks.
Educational partners and supporters
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
